Dabogratinib (TYRA-300) TBD

Phase 2

Dabogratinib (TYRA-300) TBD is one of 2 therapeutic programs targeting Upper Tract Urothelial Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Upper Tract Urothelial CarcinomaRecruiting

Upper Tract Urothelial CarcinomaPhase 2

Recruiting

Competition

Competitive Landscape

1 competitor in Upper Tract Urothelial Carcinoma

#DrugCompanyPhaseTrials

Dabogratinib

TTyra Biosciences, Inc

Phase 2

1 2

Dabogratinib (TYRA-300) TBD

TTyra Biosciences, Inc

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 2Recruiting

Upper Tract Urothelial Carcinoma

NCT07265947

Clinical

Trials by Indication[1]

Upper Tract Urothelial Carcinoma1 trial

A Phase 2A/B, Multi-center, Open-Label Study Evaluating the Efficacy and Safety of Dabogratinib (TYRA-300) in Participants With Low Grade Upper Tract Urothelial Carcinoma (SURF303)

Recruiting·TTyra Biosciences, Inc·Phase 2·NCT07265947·230 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Dabogratinib (TYRA-300) TBD. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Dabogratinib (TYRA-300) TBD. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Tyra Biosciences, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: TTyra Biosciences, Inc

Dabogratinib (TYRA-300) TBD

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Upper Tract Urothelial Carcinoma1 trial

References

Drug Info

Quick Facts

Related News